ReviewFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026
Beyond Hemostasis: Platelet Biomarkers and Vascular-Immune Crosstalk in Dengue.
Review in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Dengue is an arboviral disease with major global public health impact. Its pathophysiology involves complex interactions between the virus and the host, including the immune response and the vascular endothelium. In this context, platelets play roles beyond hemostasis, acting as key immunomodulatory cells involved in inflammation and the regulation of vascular permeability. Therefore, this review summarizes and discusses the so called classic and non-classic platelet-related and endothelial biomarkers described in dengue virus infection. Classical biomarkers include P-selectin (CD62P), PF4/CXCL4, RANTES/CCL5, CD40L, IL-1β, VEGF, integrin αIIbβ3, CD63, and platelet extracellular vesicles, all supported by broad experimental and clinical evidence. Non-classical or emerging biomarkers include TLT-1, TREM-1/sTREM-1, angiopoietins (Ang-1/Ang-2), serotonin, ferritin, dengue virus envelope domain III (EIII), and soluble endothelial molecules such as IL-1RA, sCD163, SDC-1, sVCAM-1, IL-8, and IP-10. Alone or in combination, these markers can be used/explored as prognostic tools and/or as therapeutic targets. Finally, integrating multimarker panels encompassing hemostatic, inflammatory, and endothelial pathways may improve prognostic stratification. This approach could support targeted interventions and help reduce complications such as thrombocytopenia, plasma leakage, and dengue shock.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.